Bullish & Foolish
Full ARMP fundamentals All 466 on the Survival Watch

ARMPARMATA PHARMACEUTICALS, INC.

Is Armata Pharmaceuticals struggling financially?

Yes, by its own account. Armata Pharmaceuticals told the SEC on 13 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$189.6M
Source filing
10-Q 13 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 9months

    If the burn speeds up

    Empty by Mar 2027

  • 13months

    If it eases off

    Empty by Jul 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$24.0M

÷

Cash burned over the last 12 months

$26.3M

What Armata Pharmaceuticals told the SEC

…to fund its operations for the next 12 months from the date that these condensed consolidated financial statements are issued. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The Company has prepared its condensed consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities…

ARMATA PHARMACEUTICALS, INC., Form 10-Q, filed 13 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Debt pressure is material Debt is large against the cash on hand while the business generates little to service it, which puts lenders ahead of shareholders in the queue.
  • Cash burn is narrowing It is spending 58% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt